Humacyte

Humacyte Earnings Yield

The Earnings Yield of Humacyte (HUMA) as of Nov 21, 2026 is -27.02 %. In the previous year, Earnings Yield was -98.41 % — a change of -72.54% (higher).

Earnings Yield

-27.02 %

YoY

-72.54%

Last updated:

Earnings Yield of Humacyte is 2025 -27.02 % . Earnings Yield of Humacyte was 2024 -98.41 % . It decreases by -72.54% higher compared to the previous year.

The Humacyte Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2019
-56.53 USD
Jan 1, 2020
-44.03 USD
Jan 1, 2021
-17.52 USD
Jan 1, 2022
-7.92 USD
Jan 1, 2023
-73.31 USD
Jan 1, 2024
-98.41 USD
Jan 1, 2025
-27.02 USD
The Humacyte Earnings Yield history
YEAREarnings YieldYoY
-27.02 %-72.54%
-98.41 %+34.24%
-73.31 %+825.83%
-7.92 %-54.81%
-17.52 %-60.20%
-44.03 %-22.12%
-56.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humacyte Stock analysis

What does Humacyte do? Humacyte, Inc. develops and manufactures off-the-shelf, universally implantable bioengineered human tissues and advanced tissue constructs. The company focuses on human acellular vessels (HAVs) targeting vascular repair, reconstruction, and replacement markets, including vascular trauma, AV access for hemodialysis, peripheral arterial disease, and coronary artery bypass grafting. HAVs are also being developed for pediatric heart surgery and cellular therapies like pancreatic islet cell transplantation for Type 1 diabetes. The company's technology platform uses primary human aortic vascular cells to mimic human physiology. Humacyte's products are sold to healthcare providers and medical institutions for surgical procedures requiring tissue replacement. The vascular repair and hemodialysis markets represent key segments where HAVs address unmet clinical needs. Pediatric heart surgery applications target specialized medical centers, while cellular therapy delivery focuses on diabetes treatment centers. The company's novel manufacturing paradigm enables universal implantability without immune rejection. The firm's revenue streams derive from the sale of HAVs for vascular procedures and their expansion into pediatric and cellular therapy applications. Market segments include vascular surgery, nephrology for hemodialysis access, and endocrinology for diabetes treatment. HAVs are positioned as a solution for patients requiring tissue grafts with reduced risk of rejection compared to traditional methods. Humacyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humacyte stock

Earnings Yield of Humacyte is -27.02 % in 2025.

Earnings Yield of Humacyte changed from -98.41 % to -27.02 %, representing a -72.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Humacyte since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Humacyte with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Humacyte

All Key Metrics — Humacyte